Guan Yunxuan, Wu Di, Wang Hui, Liu Ning-Ning
State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health Shanghai Jiao Tong University School of Medicine Shanghai China.
mLife. 2024 May 27;3(2):219-230. doi: 10.1002/mlf2.12118. eCollection 2024 Jun.
Human microbiomes, considered as a new emerging and enabling cancer hallmark, are increasingly recognized as critical effectors in cancer development and progression. Manipulation of microbiome revitalizing anticancer therapy from natural products shows promise toward improving cancer outcomes. Herein, we summarize our current understanding of the human microbiome-driven molecular mechanisms impacting cancer progression and anticancer therapy. We highlight the potential translational and clinical implications of natural products for cancer prevention and treatment by developing targeted therapeutic strategies as adjuvants for chemotherapy and immunotherapy against tumorigenesis. The challenges and opportunities for future investigations using modulation of the microbiome for cancer treatment are further discussed in this review.
人类微生物群被视为一种新出现的、促成癌症的标志,越来越被认为是癌症发生和发展的关键影响因素。通过天然产物调控微生物群以振兴抗癌疗法,有望改善癌症治疗效果。在此,我们总结了目前对人类微生物群驱动的影响癌症进展和抗癌治疗的分子机制的理解。我们强调了天然产物通过开发靶向治疗策略作为化疗和免疫治疗抗肿瘤发生的佐剂,在癌症预防和治疗方面的潜在转化和临床意义。本综述进一步讨论了未来利用微生物群调节进行癌症治疗研究的挑战和机遇。